5-Amino-1MQ vs AOD-9604
A side-by-side research comparison of 5-Amino-1MQ and AOD-9604 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 5-Amino-1MQ | AOD-9604 |
|---|---|---|
| Full name | 5-Amino-1-Methylquinolinium (NNMT Inhibitor) | Advanced Obesity Drug Fragment 176-191 (Modified) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Research compound |
| Mechanism | Inhibits NNMT enzyme, preventing methylation and degradation of nicotinamide. Increases intracellular NAD+ pools, activates sirtuins, and reduces fat cell size without affecting food intake. | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. |
| Molecular weight | 173.2 Da | 1815.08 Da |
| Half-life | 8-12 hours | ~2-3 hours |
| Bioavailability | High (oral) | ~90% subcutaneous |
| Typical dose | 50-100 mg | 300 mcg |
| Frequency | 1-2x daily | Daily (morning, fasted) |
| Route | Oral (capsule) | Subcutaneous injection |
5-Amino-1MQ reported benefits
- Increased cellular energy metabolism
- Reduced fat cell size
- Elevated NAD+ levels
- Does not suppress appetite
- Improved muscle stem cell function
- Oral convenience
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Related comparisons
Research and educational reference only. Not medical advice.